Universe Pharmaceuticals INC
UPC evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for UPC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · UPC
Universe Pharmaceuticals INC (UPC) is a Chinese patent medicine company facing declining revenues and recurring net losses, with a customer base shifting toward drugstore chains and pharmaceutical distributors.
Key risk: Recurring net losses
Market Cap
$3.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2025.
Universe Pharmaceuticals INC (UPC) is a Chinese patent medicine company facing declining revenues and recurring net losses, with a customer base shifting toward drugstore chains and pharmaceutical distributors.
- Revenue declined from $32.3M (FY2023) to $23.0M (FY2024) and further to $17.9M (FY2025) [sec · filed 2026-01-29].
- Net losses were $8.7M (FY2023), $8.7M (FY2024), and $3.7M (FY2025) [sec · filed 2026-01-29].
- Cash & equivalents stood at $33,592.0M as of 2025-09-30 [sec].
- Customer base shifted: drugstore chains grew from 4.49% of revenue (FY2024) to 39.69% (FY2025) [sec · filed 2026-01-29].
- R&D expenses dropped 77.8% to $0.7M in FY2025 from $3.0M in FY2024 [sec · filed 2026-01-29].
What works
- The company maintains a substantial cash position of $33,592.0M as of 2025-09-30 [sec].
- Customer diversification is improving, with drugstore chains rising to 39.69% of revenue in FY2025 from 4.49% in FY2024 [sec · filed 2026-01-29].
- The company continues to invest in R&D and does not anticipate that recent reductions will materially impair its product pipeline [sec · filed 2026-01-29].
What to weigh
- Recurring net losses and declining revenues raise uncertainty about achieving profitability [sec · filed 2026-01-29].
- The nationwide centralized drug procurement policy has materially impacted results by driving down per-unit sale prices [sec · filed 2026-01-29].
- R&D expenses have decreased sharply (77.8% in FY2025), which may affect future product competitiveness [sec · filed 2026-01-29].
- The company faces intense competition from larger pharmaceutical companies with greater financial resources [sec · filed 2026-01-29].
From the filings
Quoted directly from source documents.
Revenue decline trend
“Our revenues have declined from $32,308,735 for the fiscal year ended September 30, 2023 to $23,024,458 for the fiscal year ended September 30, 2024, and further decreased to $17,858,732 for the fiscal year ended September 30, 2025.”
SEC filings · January 29, 2026
Recurring net losses
“We have incurred recurring net losses, and our ability to achieve profitability remains uncertain, which could adversely affect our financial condition and ability to fund our operations.”
SEC filings · January 29, 2026
Sharp decline in R&D spending
“In the fiscal year ended September 30, 2025, we incurred $0.7 million in research and development expenses, a 77.8% decrease compared to the expenses in the fiscal year ended September 30, 2024.”
SEC filings · January 29, 2026
Risks & what to watch (4)›
Key risks
- Recurring net losses — The company has incurred net losses for three consecutive fiscal years, with profitability uncertain [sec · filed 2026-01-29].
- Revenue decline — Revenue dropped from $32.3M (FY2023) to $17.9M (FY2025) due to lower sales volume and selling prices [sec · filed 2026-01-29].
- Drug procurement policy impact — Centralized procurement policy drives down per-unit sale prices, materially affecting results [sec · filed 2026-01-29].
- Intense competition — Competitors with greater financial resources and rapid technological change threaten market position [sec · filed 2026-01-29].
What to watch
- Ability to reverse revenue decline and achieve profitability [sec · filed 2026-01-29].
- Impact of continued R&D spending reductions on product pipeline and innovation [sec · filed 2026-01-29].
- Further effects of China's centralized drug procurement policy on pricing and margins [sec · filed 2026-01-29].
- Customer base shift toward drugstore chains and its effect on revenue stability [sec · filed 2026-01-29].
Sources: SEC filings · Generated August 26, 2026 · How we verify sources →
Run Universe Pharmaceuticals INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Universe Pharmaceuticals INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of Apr 30, 2026- % of float
- 0.8%
- Days to cover
- 1.0
- Shares short
- 4,610
- Daily short volume (Jun 4, 2026)
- 61.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
UPC short interestFrequently asked questions
What is the AI investment thesis for Universe Pharmaceuticals INC?
Universe Pharmaceuticals INC (UPC) is a Chinese patent medicine company facing declining revenues and recurring net losses, with a customer base shifting toward drugstore chains and pharmaceutical distributors.
Who is the CEO of Universe Pharmaceuticals INC?
Mr. Gang Lai is the chief executive officer of Universe Pharmaceuticals INC (UPC).
Where is Universe Pharmaceuticals INC headquartered?
Universe Pharmaceuticals INC (UPC) is headquartered in Ji'An, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.